Reduction of dependence to cannabinoids by GLT-1 activating property of the beta-lactam antibiotic

Medical Hypotheses

Volumn 80, Issue 3, 2013, Pages 247-248

  Ulugol, Ahmet ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CANNABINOID; CEFTRIAXONE; GLUTAMATE TRANSPORTER; OPIATE;

ARTICLE; CHRONIC PAIN; DRUG DEPENDENCE; DRUG TOLERANCE; NEUROPROTECTION; NOCICEPTION; PROTEIN EXPRESSION; RECEPTOR BINDING; SYNAPTIC TRANSMISSION;

ANTI-BACTERIAL AGENTS; CANNABINOIDS; EXCITATORY AMINO ACID TRANSPORTER 2; LACTAMS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84874545248     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.11.040     Document Type: Article

References (38)

1. Seal R.P., Amara S.G. Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 1999, 39:431-456.
2. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
3. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
4. Rao V.L., Bowen K.K., Dempsey R.J. Transient focal cerebral ischemia down-regulates glutamate transporters GLT-1 and EAAC1 expression in rat brain. Neurochem Res 2001, 26:497-502.
5. Rawls S.M., Robinson W., Patel S., Baron A. Beta-lactam antibiotic prevents tolerance to the hypothermic effect of a kappa opioid receptor agonist. Neuropharmacology 2008, 55:865-870.
6. Wang M., Dong H.J., Gong Z.H. Effects of beta-lactam antibiotics on development of tolerance and dependence to morphine. Yao Xue Xue Bao 2008, 43:1094-1098.
7. Lin Y., Tian G., Roman K., Handy C., Travers J.B., Lin C.G., et al. Increased glial glutamate transporter EAAT2 expression reduces visceral nociceptive response in mice. Am J Gastrointest Liver Physiol 2009, 296:G129-G134.
8. Yan H., Li C.M., Li Y.L., Gong Z.H. Effect of glutamate transporter 1 on chronic constriction injury of sciatic nerve and morphine tolerance of rats. Yao Xue Xue Bao 2009, 44:581-585.
9. Hu Y., Li W., Lu L., Cai J., Xian X., Zhang M., et al. An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. Pain 2010, 148:284-301.
10. Rawls S.M., Zielinski M., Patel H., Sacavage S., Baron D.A., Patel D. Beta-lactam antibiotic reduces morphine analgesic tolerance in rats through GLT-1 transporter activation. Drug Alcohol Depend 2010, 107:261-263.
11. Gunduz O., Oltulu C., Buldum D., Guven R., Ulugol A. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett 2011, 491:23-25.
12. Sari Y., Sakai M., Weedman J.M., Rebec G.V., Bell R.L. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 2011, 46:239-246.
13. Gunduz O., Oltulu C., Ulugol A. Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the beta-lactam antibiotic, ceftriaxone, in mice. Pharmacol Biochem Behav 2011, 99:100-103.
14. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sci 1999, 65:675-685.
15. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 2001, 63:569-611.
16. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacol Therapeut 2002, 95:127-135.
17. Ulugol A. Modulatory role of asymmetric dimethylarginine (ADMA) in cannabinoid tolerance and dependence. Med Hypotheses 2009, 73:213-214.
18. Gunduz O., Karadag C.H., Ulugol A. Modulatory role of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in morphine tolerance and dependence in mice. J Neural Transm 2010, 117:1027-1032.
19. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., et al. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci 1992, 654:33-51.
20. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
21. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature 1998, 395:381-383.
22. Heinricher M.M., Morgan M.M., Tortorici V., Fields H.L. Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience 1994, 63:279-288.
23. Vaughan C.W., McGregor I.S., Christie M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 1999, 127:935-940.
24. 2 receptors in the spinal cord. Br J Pharmacol 2006, 149:498-505.
25. 7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, o-desmethyltramadol, via activation of descending serotonergic pathways. Anesthesiology 2010, 112:696-710.
26. 2A receptors. Eur J Pharmacol 2010, 649:183-194.
27. 1 receptor-mediated antinociception. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38:97-105.
28. Martin T.J., Eisenach J.C. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 2001, 299:811-817.
29. Taylor D.A., Fleming W.W. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 2001, 297:11-18.
30. Heinzen E.L., Pollack G.M. The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. Biochem Pharmacol 2004, 67:735-741.
31. Koch T., Höllt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Therapeut 2008, 117:199-206.
32. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self administrative behavior. Pharmacol Rev 1994, 46:293-324.
33. Dambisya Y.M., Lee T.L. Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br J Pharmacol 1996, 117:914-918.
34. Banafshe H.R., Ghazi-Khansari M., Dehpour A.R. The effect of cyclosporine on the development and expression of cannabinoid tolerance in mice. Pharmacol Biochem Behav 2005, 82:658-663.
35. Ulugol A., Karadag H.C., Ipci Y., Tamer M., Dokmeci I. The effect of WIN 55, 212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004, 371:167-170.
36. Ulugol A., Ozyigit F., Yesilyurt O., Dogrul A. The additive antinociceptive interaction between WIN 55, 212-2, a cannabinoid agonist, and ketorolac. Anesth Analg 2006, 102:443-447.
37. Gunduz O., Karadag H.C., Ulugol A. Synergistic anti-allodynic effects of nociceptin/orphanin FQ and cannabinoid systems in neuropathic mice. Pharmacol Biochem Behav 2011, 99:540-544.
38. Tappe-Theodor A., Agarwal N., Katona I., et al. A molecular basis of analgesic tolerance to cannabinoids. J Neurosci 2007, 27(15):4165-4177.